Vortioxetine versus other antidepressants in the treatment of burning mouth syndrome: An open‐label randomized trial

Adamo, Daniela; Pecoraro, Giuseppe; Coppola, Noemi; Calabria, Elena; Aria, Massimo; Mignogna, Michele Davide

doi:10.1111/odi.13602

Cited by 22 publications

(32 citation statements)

References 158 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Despite the limitations of the study, these results furtherly reinforce that novel multimodal drugs such as vortioxetine (Adamo et al, 2019 , 2021 ) recently considered in the treatment of BMS could have a role not only in pain modulation and mood improvement but also in reversing brain alterations such as WMCs and enhancing a cognitive decline in patients.…”

Section: Discussionsupporting

confidence: 73%

Burning Fog: Cognitive Impairment in Burning Mouth Syndrome

Canfora

Calabria

Cuocolo

et al. 2021

Front. Aging Neurosci.

Self Cite

View full text Add to dashboard Cite

Background: Due to its common association with chronic pain experience, cognitive impairment (CI) has never been evaluated in patients with burning mouth syndrome (BMS). The purpose of this study is to assess the prevalence of CI in patients with BMS and to evaluate its relationship with potential predictors such as pain, mood disorders, blood biomarkers, and white matter changes (WMCs).Methods: A case-control study was conducted by enrolling 40 patients with BMS and an equal number of healthy controls matched for age, gender, and education. Neurocognitive assessment [Mini Mental State Examination (MMSE), Digit Cancellation Test (DCT), the Forward and Backward Digit Span task (FDS and BDS), Corsi Block-Tapping Test (CB-TT), Rey Auditory Verbal Learning Test (RAVLT), Copying Geometric Drawings (CGD), Frontal Assessment Battery (FAB), and Trail Making A and B (TMT-A and TMT-B)], psychological assessment [Hamilton Rating Scale for Depression and Anxiety (HAM-D and HAM-A), Pittsburgh Sleep Quality Index (PSQI), Epworth Sleepiness Scale (ESS), and 36-Item Short Form Health Survey (SF-36)], and pain assessment [Visual Analogic Scale (VAS), Total Pain Rating index (T-PRI), Brief Pain Inventory (BPI), and Pain DETECT Questionnaire (PD-Q)] were performed. In addition, blood biomarkers and MRI of the brain were recorded for the detection of Age-Related WMCs (ARWMCs). Descriptive statistics, the Mann-Whitney U-test, the Pearson Chi-Squared test and Spearman's correlation analysis were used.Results: Patients with BMS had impairments in most cognitive domains compared with controls (p < 0.001**) except in RAVLT and CGD. The HAM-D, HAM-A, PSQI, ESS, SF-36, VAS, T-PRI, BPI and PD-Q scores were statistically different between BMS patients and controls (p < 0.001**) the WMCs frequency and ARWMC scores in the right temporal (RT) and left temporal (LT) lobe were higher in patients with BMS (p = 0.023*).Conclusions: Meanwhile, BMS is associated with a higher decline in cognitive functions, particularly attention, working memory, and executive functions, but other functions such as praxis-constructive skills and verbal memory are preserved. The early identification of CI and associated factors may help clinicians to identify patients at risk of developing time-based neurodegenerative disorders, such as Alzheimer's disease (AD) and vascular dementia (VD), for planning the early, comprehensive, and multidisciplinary assessment and treatment.

show abstract

Section: Discussionsupporting

confidence: 73%

Burning Fog: Cognitive Impairment in Burning Mouth Syndrome

Canfora

Calabria

Cuocolo

et al. 2021

Front. Aging Neurosci.

Self Cite

View full text Add to dashboard Cite

show abstract

“…In our study we demonstrated that both VORT and ROP used at the dose of 10 mg/kg were able to elevate the mechanical nociceptive threshold and VORT was more efficacious than ROP in this assay. Previous studies revealed analgesic properties of VORT in various pain conditions in mice [ 37 , 69 ] and humans [ 70 , 71 ] and it was suggested that the analgesic properties of VORT in chronic pain conditions were due to the increased content of serotonin and noradrenaline in the brainstem of mice [ 37 ]. Our present study is the first one that shows that VORT might also be effective in pain in the course of FM.…”

Section: Discussionmentioning

confidence: 99%

Serotonergic Neurotransmission System Modulator, Vortioxetine, and Dopaminergic D2/D3 Receptor Agonist, Ropinirole, Attenuate Fibromyalgia-Like Symptoms in Mice

Sałat

Furgała-Wojas

2021

Molecules

View full text Add to dashboard Cite

Fibromyalgia is a disease characterized by lowered pain threshold, mood disorders, and decreased muscular strength. It results from a complex dysfunction of the nervous system and due to unknown etiology, its diagnosis, treatment, and prevention are a serious challenge for contemporary medicine. Impaired serotonergic and dopaminergic neurotransmission are regarded as key factors contributing to fibromyalgia. The present research assessed the effect of serotonergic and dopaminergic system modulators (vortioxetine and ropinirole, respectively) on the pain threshold, depressive-like behavior, anxiety, and motor functions of mice with fibromyalgia-like symptoms induced by subcutaneous reserpine (0.25 mg/kg). By depleting serotonin and dopamine in the mouse brain, reserpine induced symptoms of human fibromyalgia. Intraperitoneal administration of vortioxetine and ropinirole at the dose of 10 mg/kg alleviated tactile allodynia. At 5 and 10 mg/kg ropinirole showed antidepressant-like properties, while vortioxetine had anxiolytic-like properties. None of these drugs influenced muscle strength but reserpine reduced locomotor activity of mice. Concluding, in the mouse model of fibromyalgia vortioxetine and ropinirole markedly reduced pain. These drugs affected emotional processes of mice in a distinct manner. Hence, these two repurposed drugs should be considered as potential drug candidates for fibromyalgia. The selection of a specific drug should depend on patient’s key symptoms.

show abstract

“…Recently, in two pilot clinical studies, Adamo et al tested VO in a sample of patients affected by chronic neuropathic orofacial pain (CNOP) with encouraging results, suggesting a new possibility in the management of these patients. 111 , 168 Indeed, VO demonstrated efficacy in the relief of pain, anxiety, depression and sleep disturbance, improving the quality-of-life of the patients. 111 , 168 …”

Section: Clinical Usementioning

confidence: 99%

“… 111 , 168 Indeed, VO demonstrated efficacy in the relief of pain, anxiety, depression and sleep disturbance, improving the quality-of-life of the patients. 111 , 168 …”

Section: Clinical Usementioning

confidence: 99%

“…Indeed, the progressive up-titration of the dosage until 20 mg/daily was proven to be efficacious and safe, as also suggested by several studies. 111 Nevertheless, the EU health authorities recommend initiating treatment in the elderly with a daily dose of 5 mg (and advise caution when prescribing VO at a dose of 10 mg/day), due to the fact that exposure to VO may increase by up to 27% in healthy volunteers aged 65 years as compared with those aged 45 years, who had received multiple doses of 10 mg/day. 112 …”

Section: Dosagementioning

confidence: 99%

See 1 more Smart Citation

Vortioxetine as a new frontier in the treatment of chronic neuropathic pain: a review and update

Adamo

Calabria

Coppola

et al. 2021

Therapeutic Advances in Psychopharmacology

Self Cite

View full text Add to dashboard Cite

Chronic neuropathic pain (CNP) is a disabling medical condition that impairs the health-related quality-of-life of affected patients. A high prevalence of anxiety, depression, sleep disturbance and cognitive impairment has frequently been reported in association with CNP, making the management of this disease complex and often multidisciplinary. Dual-acting agents such as selective serotonin and noradrenalin reuptake inhibitors (SNRIs) are considered particularly useful in the modulation of pain and in treatment of the mood disorders frequently associated with CNP. Recent evidence suggests that the top-down inhibitory control of pain involves the engagement and enhancement of descending endogenous opioidergic, cannabinoid and serotonergic systems, with the effect of serotonin being particularly related to the receptor subtypes that are preferentially activated; indeed serotonin induces analgesia via activation of 5-HT7 receptors and hyperalgesia via activation of 5-HT3 receptors. Vortioxetine (VO) is a novel multimodal serotonergic antidepressant with a unique mechanism of action. It has been demonstrated recently in experimental and clinical studies to have efficacy on pain hypersensitivity and on mood disorders. This drug inhibits the serotonin transporter with a high affinity, antagonises the 5-HT3, 5-HT1D and 5HT7 serotonin receptors, and activates the 5-HT1A and 5-HT1B receptors. In clinical studies, VO has proved effective at a dose of 10–20 mg/daily in short- and long-term treatment of patients with chronic orofacial pain, demonstrating a higher rate of clinical response and remission, a better acceptability, safety rate and tolerability, and a lower latency of action compared with other antidepressants. In the light of these recent findings, VO may be considered as a new pharmacological treatment also in relation to various types of CNP, particularly in elderly patients with concomitant mood disorders and cognitive impairment. The purpose of this review is to provide an up-to-date overview of the pharmacology and clinical applications of VO and to highlight its potential therapeutic properties and advantages in the management of CNP.

show abstract

Vortioxetine versus other antidepressants in the treatment of burning mouth syndrome: An open‐label randomized trial

Cited by 22 publications

References 158 publications

Burning Fog: Cognitive Impairment in Burning Mouth Syndrome

Burning Fog: Cognitive Impairment in Burning Mouth Syndrome

Serotonergic Neurotransmission System Modulator, Vortioxetine, and Dopaminergic D2/D3 Receptor Agonist, Ropinirole, Attenuate Fibromyalgia-Like Symptoms in Mice

Vortioxetine as a new frontier in the treatment of chronic neuropathic pain: a review and update

Contact Info

Product

Resources

About